The study utilized the Vaccine Safety Datalink and included children who received the first dose of a measles-containing vaccine between 12 and 23 months old during the study period of January 1, 2003 to September 20, 2015.
Investigators assessed the frequency of bilateral independent periodic discharges in patients experiencing electrographic seizures and their effect on patient mortality and clinical outcomes.
Eslicarbazepine acetate is well tolerated and may be effective for treating patients with post-stroke epilepsy.
Adjunctive brivaracetam may provide long term effectiveness in adults who have not seen optimal results with other common treatments.
Children with Dravet syndrome receiving fenfluramine experienced improvements in emotional regulation, behavioral regulation, and planning and organization abilities.
Researchers aimed to identify risk factors associated with a psychiatric event following a first prescription for levetiracetam.
Patients taking an active treatment regimen consisting of SSRIs, TCAs, or antipsychotic medications are less likely to experience a seizure in the epilepsy monitoring unit.
Perampanel at a median maximum dose of 6 mg (1 to 20 mg) is associated with good long-term treatment retention and sustained efficacy.
Investigators aimed to determine whether utilization of enzyme-inducing antiepileptic drugs increases vitamin D requirements.
Low total benzodiazepine dosing is linked to longer intensive care unit stays and seizure duration in children.
Patients at high risk for SUDEP may shift to a lower risk group over time.
Tolerance to cannabidiol may exist, potentially limiting its efficacy as an antiseizure therapy in the long-term management of epilepsy.
Patients with focal epilepsy and comorbid migraine may have greater depressive symptoms compared with individuals without the comorbidity.
Investigators examined whether a reduction in titration rates utilized in earlier trials would reduce the incidence of DRESS in patients taking cenobamate.
Safety and efficacy were examined in adults aged 60 compared with adults younger than 60.
Antiepileptic drugs are more likely to be tolerated by patients who have not experienced adverse drug reactions to previous antiepileptic drugs.
Midazolam nasal spray, a novel benzodiazepine formulation, may be a safe, long-term treatment option for acute seizure episodes.
In the retrospective study, the primary reason for initiating perampanel was poor seizure control.
Aquestive Therapeutics announced that the FDA has approved Sympazan oral film as adjunctive treatment of seizures associated with LGS in patients aged ≥2 years old.
Researchers used analytic techniques from circular statistics to quantify the prevalence, frequency, and strength of seizure cycles in patients with epilepsy.
Better social competence and adaptive behavior was achieved by seizure-free patients at post-surgery follow-ups compared with patients with persistent seizures (P <.05).
The Food and Drug Administration (FDA) approved the treatment in June 2018, making it the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol, as well as the first treatment indicated for patients with Dravet syndrome.
The researchers sought to identify risk factors for seizures in this population by reviewing hospital records.
HFOs were predictors of good or poor surgical outcome in 69.2% of patients, resulting in a modest validation of the researchers' hypothesis.
It is likely that both maternal age and socioeconomic status contribute to the higher rates of pregnancy in WWE compared with women without epilepsy.
There are considerations for treating these seizures as part of the overall goals of palliative care, which include the family's experience.
Rectal acetaminophen reduces rates of second febrile seizure in children during the course of the same febrile illness when given rectally soon after initial seizure.
Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing.
Drugs with a Schedule V classification have proven medical use and low abuse potential.
The Company states that the NDA is supported by robust clinical trial data, including patients studies where more than 1600 seizures were treated with Valtoco nasal spray.
Neurology Advisor Articles
- Surgical, Nonsurgical Treatments for Chronic Migraine: Evidence and Relevancy
- Autoimmune Diseases Increase Hippocampal Sclerosis Risk in Nonagenarians
- Neurofilament Light Biomarkers Identify Alzheimer Disease Risk in Down Syndrome
- Myoclonic-Atonic Seizures and Lennox-Gastaut Syndrome Present With Overlapping Features, Difficulty in Diagnosis
- Tap Water in Neti Pot Linked to Brain Infection, Death From Balamuthia mandrillaris
- Addressing Neuropsychiatric Symptoms in Huntington Disease: Expert Interview
- Intellectual Engagement Linked to Cognitive Performance Later
- Thienopyridine Agents and Patent Foramen Ovale Closures Reduce Migraines
- Volume Perfusion CT Helps Differentiate Ictal Stroke Mimics, but Not Postictal, From Acute Ischemic Stroke
- Side Effects, Tolerability of Newer DMTs Similar in Pediatric, Adult Multiple Sclerosis